These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34645493)

  • 1. DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer.
    Wang J; Li J; Chen R; Yue H; Li W; Wu B; Bai Y; Zhu G; Lu X
    Clin Epigenetics; 2021 Oct; 13(1):190. PubMed ID: 34645493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
    Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
    Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
    Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
    Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylomic Signatures of High Grade Serous Ovarian Cancer.
    Cardenas H; Fang F; Jiang G; Perkins SM; Zhang C; Emerson RE; Hutchins G; Keer HN; Liu Y; Matei D; Nephew K
    Epigenetics; 2021 Nov; 16(11):1201-1216. PubMed ID: 33289590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
    Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
    Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
    Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
    BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
    Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
    JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
    Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
    Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
    Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
    Reyes HD; Devor EJ; Warrier A; Newtson AM; Mattson J; Wagner V; Duncan GN; Leslie KK; Gonzalez-Bosquet J
    Sci Rep; 2019 Nov; 9(1):17996. PubMed ID: 31784612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer.
    Sarkar S; Saha SA; Swarnakar A; Chakrabarty A; Dey A; Sarkar P; Banerjee S; Mitra P
    J Ovarian Res; 2024 Aug; 17(1):159. PubMed ID: 39095849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
    Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
    Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
    Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Silva R; Glennon K; Metoudi M; Moran B; Salta S; Slattery K; Treacy A; Martin T; Shaw J; Doran P; Lynch L; Jeronimo C; Perry AS; Brennan DJ
    Int J Cancer; 2023 Jul; 153(1):120-132. PubMed ID: 36883413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
    Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.